Joe E. Kiani Sells 104,870 Shares of Masimo Corp. (MASI) Stock
Masimo Corp. (NASDAQ:MASI) CEO Joe E. Kiani sold 104,870 shares of the firm’s stock in a transaction on Tuesday, November 29th. The shares were sold at an average price of $62.27, for a total transaction of $6,530,254.90. Following the completion of the transaction, the chief executive officer now owns 119,241 shares in the company, valued at $7,425,137.07. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Masimo Corp. (NASDAQ:MASI) opened at 61.87 on Thursday. The stock’s 50 day moving average is $59.35 and its 200-day moving average is $55.78. Masimo Corp. has a 12-month low of $33.03 and a 12-month high of $62.62. The company has a market capitalization of $3.07 billion, a P/E ratio of 29.87 and a beta of 0.98.
Masimo Corp. (NASDAQ:MASI) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported $0.52 EPS for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.10. The business had revenue of $167.60 million for the quarter, compared to analyst estimates of $165.51 million. Masimo Corp. had a net margin of 16.31% and a return on equity of 29.42%. The firm’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.36 earnings per share. On average, equities analysts predict that Masimo Corp. will post $2.14 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2016/12/01/joe-e-kiani-sells-104870-shares-of-masimo-corp-masi-stock.html.
A number of analysts have weighed in on MASI shares. Zacks Investment Research downgraded shares of Masimo Corp. from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 4th. Wedbush reissued an “outperform” rating and issued a $75.00 price target on shares of Masimo Corp. in a report on Monday, November 14th. BTIG Research reissued a “hold” rating on shares of Masimo Corp. in a report on Friday, August 5th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $55.00 price target (up from $52.00) on shares of Masimo Corp. in a report on Friday, August 5th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $55.00.
A number of institutional investors have recently modified their holdings of MASI. D.A. Davidson & CO. increased its position in shares of Masimo Corp. by 42.8% in the third quarter. D.A. Davidson & CO. now owns 1,713 shares of the company’s stock worth $101,000 after buying an additional 513 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Masimo Corp. by 76.9% in the second quarter. Victory Capital Management Inc. now owns 2,148 shares of the company’s stock worth $113,000 after buying an additional 934 shares during the last quarter. Acrospire Investment Management LLC increased its position in shares of Masimo Corp. by 22.2% in the third quarter. Acrospire Investment Management LLC now owns 2,200 shares of the company’s stock worth $131,000 after buying an additional 400 shares during the last quarter. Tower Research Capital LLC TRC purchased a new position in shares of Masimo Corp. during the second quarter worth $116,000. Finally, First Quadrant L P CA purchased a new position in shares of Masimo Corp. during the third quarter worth $138,000. Institutional investors and hedge funds own 82.49% of the company’s stock.
Masimo Corp. Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
Receive News & Stock Ratings for Masimo Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corp. and related stocks with our FREE daily email newsletter.